Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy skeptism during a time when the ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...